Study of Epstein-Barr Virus Antibodies and Cancer Risk in Adults Aged 30 to 69 in Southern China

What this Trial Is About

Researchers are conducting a prospective cohort study in Southern China to explore the links between Epstein-Barr Virus EBV antibody levels and the risk of developing various cancers. The study aims to determine if EBV is associated with cancer types beyond those already known, like lymphomas, nasopharyngeal carcinoma, and stomach cancer, and to understand the overall cancer burden related to EBV in this region. Molecular evidence suggests EBV plays a role in multiple cancers, but comprehensive population data is still needed. Participants are healthy adults from Zhongshan and Wuzhou cities, aged 30 to 69 years. At enrollment, all participants undergo EBV antibody tests, including VCA-IgA and EBNA1-IgA. The study follows them annually for up to 10 years to monitor cancer incidence, vital status, and immigration status. This observational study does not involve treatment but focuses on collecting data and biological samples to analyze cancer risks related to EBV. During the study, participants will be assessed annually through follow-up visits to record new cancer diagnoses and overall health outcomes. Researchers measure cancer incidence as the primary outcome and all-cause mortality as a secondary outcome over a 10-year period. The study tracks participants health status and location changes to ensure accurate long-term monitoring. This long-term observational approach aims to provide valuable insights into EBVs role in cancer development.

Epstein-Barr Virus and Cancer Risks